Novartis Faces Setback as Court Rules Against Blocking Generic Heart Drug

Novartis has faced a setback in its legal efforts to block the approval of a generic version of its top-selling heart failure drug, Entresto. A U.S. District Court ruled against Novartis, allowing MSN Pharmaceuticals to proceed with its generic version of the drug, though legal challenges remain regarding patent infringement. Entresto generated over $6 billion in revenue last year, making this case crucial for Novartis as it continues to appeal the decision. #Novartis #Entresto #Pharma #india Generics #Healthcare